Table 2.

Patients on PancSeq protocol who underwent treatment with experimental agents

IdentifierGenderAge (y)StagePrebiopsy treatments for advanced diseaseGenomic featuresPost-biopsy treatments
0400068_T1M44MetastaticNo prior chemotherapyBRCA2, KRASFOLFIRINOX–PARP inhibitor (OL)
0400075_T1F58MetastaticNo prior chemotherapyCHEK2, KRAS, gBRCA1FOLFIRINOX–PARP inhibitor vs. placebo (CT)
0400078_T1F39MetastaticGA/JAK inhibitor (CT), FOLFIRINOXKRAS, CDKN2A, gBRCA2UBA1 inhibitor (CT)–PARP inhibitor (OL)
0400096_T1M57MetastaticNo prior chemotherapyKRAS, CDKN2AFOLFIRINOX–GA/anti-MUC5AC mAb (CT)
0400097_T1M48MetastaticNo prior chemotherapyKRASFOLFIRINOX–GA–CHK1/2 inhibitor (CT)
0400117_T2F65MetastaticFOLFIRINOX, GAKRAS, CDKN2API3K/mTOR inhibitor/CDK4/6 inhibitor (CT)
0400127_T1F60MetastaticNo prior chemotherapyKRAS, CDKN2AFOLFIRINOX–GA–CDK4/6 inhibitor/MEK1/2 inhibitor (CT)
0400151_T2F61MetastaticFOLFIRINOX, GAKRAS, CDKN2ACDK2/5/9 inhibitor (CT)
0400165_T1F73MetastaticFOLFIRINOXERCC2, KRASGA–prostaglandin E2 receptor EP4 antagonist (CT)
0400172_T1M58MetastaticNo prior chemotherapyBRAF, CDKN2AFOLFIRINOX–MEK1/2 inhibitor (OL)–GA–ERK1/2 inhibitor (SP-IND)
0400174_T1M77MetastaticNo prior chemotherapyATM (biallelic), KRAS, CDKN2AGA–5FU/LV/Nal-Iri–PARP inhibitor (OL)
0400177_T1F64MetastaticFOLFOX, 5FU/LV/Nal-Iri, GAKRAS, NBN, FANCMPARP inhibitor/CDK1/2/5/9 inhibitor (CT)
0400197_T1F65MetastaticFOLFIRINOX, GABRAF, FGFR1 (amplification)MEK1/2 inhibitor (OL)–ERK1/2 inhibitor (SP-IND)
0400202_T1M83MetastaticROS1 inhibitor (CT)CDKN2A, ROS1 (translocation)ROS1 inhibitor (OL)–ROS1 inhibitor (OL)
0400242_T1F63MetastaticNo prior chemotherapyKRAS, CDKN2A, gBRCA1FOLFIRINOX–PARP inhibitor vs. placebo (CT)
0400245_T1M57MetastaticNo prior chemotherapyKRASFOLFIRINOX–anti–PD-1 mAb/CXCR4 antagonist (CT)–GA
0400270_T1F66MetastaticGA, Cape, 5FU/LV/Nal-Iri, FOLFOXKRASAnti–PD-1 mAb/anti-GITR mAB agonist (CT)
  • NOTE: Bolded genes indicate those genetic alterations that guided choice of experimental therapy. A “g” preceding the gene name refers to “germline.” GA, gemcitabine plus albumin-bound paclitaxel; FOLFIRINOX, 5-FU/leucovorin/irinotecan/oxaliplatin; FOLFOX, 5-FU, leucovorin, oxaliplatin; mAb, monoclonal antibody; Nal-Iri, nanoliposomal irinotecan; Cape, capecitabine; CT, clinical trial; OL, off-label; SP-IND, single-patient investigational new drug application.